Clinical Trial Update: Effect of Exenatide Plus Metformin vs. Insulin Aspart Plus Metformin on Glycemic Control and Hypoglycemia in Patients With Type 2 Diabetes [Phase 3]

View source ↗

Summary

A Phase 3 trial compared Exenatide plus Metformin with Insulin Aspart plus Metformin in Type 2 Diabetes to assess glycemic control and hypoglycemia; results wer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• EXENATIDE (EXENATIDE)
• Insulin aspart (insulin aspart)

Snippet

Sponsor: AstraZeneca | Conditions: Type 2 Diabetes Mellitus | Phase 3 | Status: COMPLETED | Results posted: 2010-08-23